^
    2d
    Calciphylaxis as a Rare Complication Associated with Pemigatinib Treatment-A Case Report. (PubMed, Curr Oncol)
    This case highlights the importance of early recognition of cutaneous lesions in patients on FGFR inhibitors. Prompt cessation of therapy, management of metabolic derangements, and consideration of sodium thiosulfate may be lifesaving.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 fusion
    |
    Pemazyre (pemigatinib)
    2d
    Integrative multi-omics and single-cell analysis identifies EGFR pathway activation and metabolic reprogramming as potential synthetic lethal vulnerabilities in resistance to the FGFR inhibitor AZD4547. (PubMed, J Transl Med)
    This study establishes a comprehensive multi-omics atlas of resistance to the FGFR inhibitor AZD4547, delineating convergent mechanisms of metabolic reprogramming and EGFR-mediated bypass signaling. Our findings characterize the resistance as a dynamic network rewiring and nominate rational combination strategies to overcome this therapeutic bottleneck. While FGFR-EGFR co-inhibition is experimentally supported, metabolic co-targeting remains a computationally derived, hypothesis-generating strategy.
    Journal
    |
    PPFIBP2 (PPFIA Binding Protein 2) • FSCN1 (Fascin Actin-Bundling Protein 1)
    |
    Balversa (erdafitinib) • Truseltiq (infigratinib) • Pemazyre (pemigatinib) • fexagratinib (ABSK091)
    5d
    From progression to complete remission - a case study of successful pemigatinib treatment in a patient with metastatic FGFR2+ cholangiocarcinoma. (PubMed, Klin Onkol)
    This case demonstrates the significant therapeutic potential of pemigatinib in a patient with metastatic cholangiocarcinoma with FGFR2 fusion, where complete disease remission was achieved after previous progression on standard treatment.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • BICC1 (BicC Family RNA Binding Protein 1)
    |
    FGFR2 fusion • FGFR fusion
    |
    Pemazyre (pemigatinib)
    16d
    POD1UM-204: Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. (clinicaltrials.gov)
    P2, N=206, Completed, Incyte Corporation | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon)
    |
    PD-L1 expression • MSI-H/dMMR • FGFR mutation
    |
    Pemazyre (pemigatinib) • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360) • tuparstobart (INCAGN2385) • verzistobart (INCAGN2390)
    19d
    Pemigatinib-Associated Psoriasis in a Patient With Cholangiocarcinoma. (PubMed, Cureus)
    Recognition and management of dermatologic adverse effects are critical to minimizing morbidity in the setting of life-prolonging oncologic treatments. Given the limitations of a single-case inference, further surveillance and study are needed to determine whether patients with pre-existing psoriasis may be at increased risk.
    Journal
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    Pemazyre (pemigatinib)
    23d
    FGFR2 Fusion Gene-Positive Solid Tumors (PubMed, Gan To Kagaku Ryoho)
    Pemigatinib (approved in 2021) demonstrated a response rate of 35.5%, futibatinib (approved in 2023) showed a response rate of 42%, and tasurgratinib (approved in 2024) achieved a response rate of 30.2%. Polyclonal on-target resistance to pan-FGFR inhibitors and increasing of FGFR2 kinase domain resistance mutations based on treatment history has been reported. Novel therapeutics, such as highly selective FGFR2 inhibitors and next-generation inhibitors, are developed and are expected to improve prognosis for patients with FGFR2 fusion-positive solid tumors.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 mutation • FGFR2 fusion • FGFR fusion
    |
    Lytgobi (futibatinib) • Pemazyre (pemigatinib) • Tasfygo (tasurgratinib)
    26d
    Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial. (PubMed, J Clin Oncol)
    This was the largest, first-line, randomized, phase 3 trial of a targeted therapy for advanced FGFR2-rearranged cholangiocarcinoma. Pemigatinib demonstrated prolonged median PFS compared with chemotherapy, with no new safety findings.
    P3 data • Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 rearrangement
    |
    cisplatin • gemcitabine • Pemazyre (pemigatinib)
    1m
    Improving public cancer care by implementing precision medicine in Norway (2023-507894-16-00)
    P1/2, N=1000, Recruiting, Oslo University Hospital HF | N=6000 --> 1000
    Enrollment change
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Tafinlar (dabrafenib) • Rozlytrek (entrectinib) • imatinib • Alecensa (alectinib) • Cotellic (cobimetinib) • bortezomib • Piqray (alpelisib) • Zejula (niraparib) • Retevmo (selpercatinib) • Zykadia (ceritinib) • fulvestrant • Jemperli (dostarlimab-gxly) • Pemazyre (pemigatinib) • Tepmetko (tepotinib) • Tabrecta (capmatinib) • dexamethasone • Erivedge (vismodegib) • melphalan • dactinomycin • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • hydroxyurea
    1m
    PA 2506: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (2025-522431-34-00)
    P1/2, N=1200, Not yet recruiting, Region Hovedstaden
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • Mekinist (trametinib) • Xalkori (crizotinib) • erlotinib • Tafinlar (dabrafenib) • Vitrakvi (larotrectinib) • gemcitabine • paclitaxel • 5-fluorouracil • capecitabine • Retevmo (selpercatinib) • albumin-bound paclitaxel • oxaliplatin • irinotecan • Pemazyre (pemigatinib) • axitinib • Erivedge (vismodegib) • leucovorin calcium • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    1m
    FGFR1 but not S6K1/2 drives intrinsic BRAF inhibitor resistance in melanoma. (PubMed, Cell Death Discov)
    Instead, a pooled CRISPR kinome knockout screen uncovered FGFR1 as a key resistance driver, and indeed intrinsic BRAFi resistance was partially to fully reversible in 6 cell lines by the FDA-approved pan-FGFR inhibitor pemigatinib. Overall, our results suggest that although changes in pS6 are an excellent marker of intrinsic BRAFi resistance, the S6K1/2-S6 axis itself is not primarily responsible, and instead that FGFR1 is worth further translational study in the context of intrinsic BRAFi resistance.
    Journal
    |
    FGFR1 (Fibroblast growth factor receptor 1)
    |
    Pemazyre (pemigatinib)
    2ms
    A Phase Ib/II Study of Pemigatinib in Combination with Paclitaxel in Patients with Gastric Cancer with FGFs/FGFRs Alterations. (PubMed, Cancer Res Treat)
    Pemigatinib plus paclitaxel demonstrated antitumor activity with an acceptable safety profile in FGFR2-amplified gastric cancer. Further investigation is warranted to elucidate resistance mechanisms and validate these findings in larger cohorts.
    P1/2 data • Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 fusion
    |
    paclitaxel • Pemazyre (pemigatinib)
    2ms
    Real-world patient characteristics and utilization patterns in patients with cholangiocarcinoma who received pemigatinib in the United States of America. (PubMed, ESMO Real World Data Digit Oncol)
    The most common baseline regimen was gemcitabine + cisplatin (34.4%). Treatment patterns, adherence, OS, HCRU, and costs demonstrated consistent trends across racial subgroups. Real-world pemigatinib treatment patterns and survival outcomes were consistent with findings from clinical trials and support continued use of pemigatinib across diverse patient groups as a key second-line treatment for CCA.
    Journal • Real-world evidence
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 fusion
    |
    cisplatin • gemcitabine • Pemazyre (pemigatinib)